Ji Soo Park

Title: Ji Soo Park: Innovator in Human Thrombopoietin Derivatives

Introduction

Ji Soo Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of human thrombopoietin derivatives. His work focuses on enhancing platelet production, which is crucial for patients undergoing various medical treatments.

Latest Patents

Ji Soo Park holds a patent for "Human thrombopoietin comprising glycosylation sited at residues 157 and 164." This invention relates to novel human thrombopoietin (hTPO) derivatives and the process of their preparation. The innovation involves introducing sugar chains into native hTPO by substituting specific amino acids, resulting in hTPO derivatives with enhanced activities that promote platelet production in vivo. These derivatives have potential applications in treating thrombocytopenia associated with anticancer therapy or bone marrow transplantation.

Career Highlights

Throughout his career, Ji Soo Park has worked with prominent organizations, including Daewoong Pharmaceutical Co., Ltd. and the Korea Institute of Science and Technology. His experience in these institutions has allowed him to advance his research and contribute to significant medical innovations.

Collaborations

Ji Soo Park has collaborated with several professionals in his field, including Joo Young Chung and Sang Kyu Park. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.

Conclusion

Ji Soo Park's contributions to the field of biotechnology, particularly through his patent on human thrombopoietin derivatives, highlight his role as an innovator. His work has the potential to significantly improve treatments for patients with low platelet counts.